SCHEMBL2929968

SCHEMBL2929968

Cc1n[nH]c2nc(-c3ccc(F)cc3)c(-c3ccnc(N[C@@H](C)c4ccccc4)n3)cc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 4/20 0.52
PRKD3 O94806 1/20 0.52
MAP4K4 O95819 1/20 0.52
LCK P06239 1/20 0.52
LYN P07948 1/20 0.52
MAPK1 P28482 1/20 0.52
AKT2 P31751 1/20 0.52
FLT4 P35916 1/20 0.52
FLT3 P36888 1/20 0.52
FRK P42685 1/20 0.52
MAPK8 P45983 1/20 0.52
MAPK9 P45984 1/20 0.52
CSNK1A1 P48729 1/20 0.52
CSNK1D P48730 1/20 0.52
GSK3A P49840 1/20 0.52
GSK3B P49841 1/20 0.52
CSNK1G2 P78368 1/20 0.52
MAP4K2 Q12851 1/20 0.52
DYRK1A Q13627 1/20 0.52
ERBB4 Q15303 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2929971 1.00 MAPK13 (0.52) MAPK13PRKD3MAP4K4LCKLYN
SCHEMBL4408488 0.84 MAPK13 (0.55) MAPK13PRKD3MAP4K4LCKLYN
SCHEMBL4408485 0.84 MAPK13 (0.55) MAPK13PRKD3MAP4K4LCKLYN
SCHEMBL4406273 0.83 MAPK13 (0.51) MAPK13PRKD3MAP4K4LCKLYN
SCHEMBL4406271 0.83 MAPK13 (0.51) MAPK13PRKD3MAP4K4LCKLYN
SCHEMBL4415845 0.78 MAPK13 (0.52) MAPK13PRKD3MAP4K4LCKLYN
SCHEMBL4415840 0.78 MAPK13 (0.52) MAPK13PRKD3MAP4K4LCKLYN
SCHEMBL27597808 0.78 MAPK13 (0.59) MAPK13PRKD3MAP4K4LCKLYN
SCHEMBL2932336 0.77 MAP4K4 (0.49) MAPK13PRKD3MAP4K4MAPK1FLT4
SCHEMBL2933510 0.77 RPS6KB1 (0.52) MAPK13PRKD3MAP4K4LCKLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 MAPK13 36/4885PRKD3 221/4885MAP4K4 24/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK13 37/4885PRKD3 126/4885MAP4K4 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.